EMA’s human medicines committee (CHMP) recommended twelve medicines for approval at its July 2026 meeting. The committee recommended granting marketing authorisations for three medicines to treat adults with primary hypercholesterolaemia or mixed dyslipidaemia, conditions that cause high cholesterol levels in the blood:Lyrokaul(lerodalcibep) is an injection that patients can self-administer monthly;Evlarco(obicetrapib / ezetimibe) andUbeslo(obicetrapib) are both oral formulations to be taken daily. All three medicines are for use in addition to diet and can be taken alone or in combination with other lipid-lowering therapies.
EMA - European Medicines Agency · March 30, 2023
CHMP meeting highlights: July 2026 – twelve medicines recommended for approval
Original title: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 July 2026
CHMP recommended marketing authorisations for twelve medicines including three for hypercholesterolaemia and mixed dyslipidaemia.
Published by EMA - European Medicines Agency. HealthSignal links to the original document; the summary above is extracted from the source text.